<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300257</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01107</org_study_id>
    <nct_id>NCT04300257</nct_id>
  </id_info>
  <brief_title>Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care</brief_title>
  <official_title>Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SwissSarcomaNetwork</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kantonsspital Winterthur KSW</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary significance of this project is to perform a detailed analysis to assess the
      diagnostics, treatment and follow-up care, to develop a prediction model for future patient
      selection regarding various diagnostic and treatment procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the framework of interdisciplinary cooperation for a sarcoma problem, predictive and
      prognostic criteria will be developed that improve the treatment and particularly outcome.

      The outcome variables include patient characteristics, tumor types and characteristics,
      histology, management and treatment strategies as well as recurrence rate and overall
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Diagnosis,</measure>
    <time_frame>5 years</time_frame>
    <description>Data collected in the registry will be evaluated and analyzed to determine criteria to improve treatment strategies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>distant metastasis,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biopsy taken by operating surgeon-radiologist-team,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathology centrally reviewed,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgery (yes/no),</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical margin status,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>surgery performed by dedicated surgeon,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation Therapy (yes/no),</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy (yes/no),</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>decision of board carried out,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Status at last contact,</measure>
    <time_frame>5 years</time_frame>
    <description>s.o.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Sarcoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from bone or soft tissue tumors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Malignant and intermediate and selected benign bone or soft tissue tumors, acc. to the
             WHO coding list of the SSN

          -  Female and male subjects of all ages

        Exclusion Criteria:

          -  Documented objection of subsequent use of personal health data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Fuchs, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>SwissSarcomaNetwork</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Fuchs, Prof.</last_name>
    <phone>+41 52 266 25 33</phone>
    <email>bruno.fuchs@ksw.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Wunderli</last_name>
    <phone>+41 52 266 24 88</phone>
    <email>sandra.wunderli@ksw.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SwissSarcomaNetwork</name>
      <address>
        <city>Winterthur</city>
        <state>ZÃ¼rich</state>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Wunderli</last_name>
      <phone>+41 52 266 24 88</phone>
      <email>sandra.wunderli@ksw.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017 Feb;110:94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8. Review.</citation>
    <PMID>28109409</PMID>
  </results_reference>
  <results_reference>
    <citation>Abarca T, Gao Y, Monga V, Tanas MR, Milhem MM, Miller BJ. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol. 2018 Jun;117(7):1479-1486. doi: 10.1002/jso.25052. Epub 2018 Apr 6.</citation>
    <PMID>29633281</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma, Epithelioid</keyword>
  <keyword>Sarcoma, Soft Tissue</keyword>
  <keyword>Sarcoma, Spindle Cell</keyword>
  <keyword>Sarcoma, Bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

